Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions
Cancers · 03.09.2025 · 17 (17) · 2898
DOI: 10.3390/cancers17172898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 03.09.2025. Verfasst von Saeed Rafii und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mediclinic City Hospital, Dubai P.O. Box 505004, United Arab Emirates. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Burjeel Cancer Institute, Abu Dhabi, United Arab Emirates.
Abstract (Originalsprache)
Background
Chimeric Antigen Receptor (CAR) T-cell therapy has transformed the treatment of hematological malignancies, yet its application in solid tumors remains constrained by unique biological and logistical barriers.
Objective
This review critically examines the evolving landscape of CAR T-cell therapy in solid malignancies, with a focus on antigen heterogeneity, the immunosuppressive tumor microenvironment, and risks of on-target, off-tumor toxicity.
Methods
We outline recent advances in CAR engineering, including co-stimulatory optimization, dual- and multi-antigen targeting, armored CARs, and gene-edited constructs designed to enhance persistence and anti-tumor activity. Clinical progress is highlighted by recent FDA approvals of genetically modified T-cell therapies in synovial sarcoma and melanoma, underscoring the potential for broader solid tumor application. Additionally, we synthesize early-phase clinical trial findings across multiple solid tumor types (e.g., lung, colorectal, ovarian, glioblastoma), and discuss innovative approaches such as regional delivery, checkpoint blockade combinations, and incorporation of chemokine receptors for improved tumor infiltration. The review also considers future strategies, including artificial intelligence-guided target discovery and rational trial design to overcome translational bottlenecks.
Conclusions
With expanding clinical experience and continued technological innovation, CAR T-cell therapy is steadily transitioning from an experimental strategy to a therapeutic reality in solid tumors, poised to reshape the future of cancer immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Mediclinic City Hospital, Dubai P.O. Box 505004, United Arab Emirates.
- Emirates Oncology Society, Dubai P.O. Box 6600, United Arab Emirates.
- Gulf Cancer Society, P.O. Box 26733, Alsafa 13128, Kuwait.
- Department of Oncology, Clemenceau Medical Center, Dubai 112963, United Arab Emirates.
- Department of Oncology, Burjeel Hospital Oman, 3521 Way, Muscat 112-1465, Oman.
- Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi P.O. Box 92510, United Arab Emirates.
ORCID-Profile: Saeed Rafii, Ashok Sebastian Komaranchath, Charbel Khalil, Siddig Ibrahim Abdelwahab, Ahmad Y Abuhelwa, Humaid O Al-Shamsi
Förderung
- Burjeel Cancer Institute, Abu Dhabi, United Arab Emirates
Zitieren
APA
Rafii, S., Mukherji, D., Komaranchath, A. S., Khalil, C., Iqbal, F., Abdelwahab, S. I., Abyad, A., Abuhelwa, A. Y., Gandikota, L., & Al-Shamsi, H. O. (2025). Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers, 17(17), 2898. https://doi.org/10.3390/cancers17172898
Vancouver
Rafii S, Mukherji D, Komaranchath AS, Khalil C, Iqbal F, Abdelwahab SI, et al. Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers. 2025;17(17):2898. doi:10.3390/cancers17172898
BibTeX
@article{Rafii2025,
author = {Rafii, Saeed and Mukherji, Deborah and Komaranchath, Ashok Sebastian and Khalil, Charbel and Iqbal, Faryal and Abdelwahab, Siddig Ibrahim and Abyad, Amin and Abuhelwa, Ahmad Y and Gandikota, Lakshmikanth and Al-Shamsi, Humaid O},
title = {Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions},
journal = {Cancers},
year = {2025},
volume = {17},
number = {17},
pages = {2898},
doi = {10.3390/cancers17172898}
}
EUVIMED